Dr. Sanket Mehta
Surgical Oncologist
GI, HPB, Gynaecological & Peritoneal Cancers
MBBS, MS · President, Society of Peritoneal Surface Oncology of India
- Experience
- 21+ years
- Speaks
- English · Hindi
Cancers treated
- Gastrointestinal
- Gynaecological
About Dr. Sanket Mehta
Dr. Sanket Mehta is a surgical oncologist who specialises in cytoreductive surgery and HIPEC, in which heated chemotherapy is delivered inside the abdomen to treat cancer that has spread there. Dr. Mehta treats advanced gastrointestinal, liver and pancreas, ovarian and peritoneal surface cancers. Dr. Mehta has performed over 800 cytoreductive surgeries and more than 450 laparoscopic and robotic cancer surgeries, and co-founded the Society of Peritoneal Surface Oncology of India and the Indian HIPEC Registry.
Treatments offered
Peritoneal & HIPEC
- Cytoreductive surgery and HIPEC
- PIPAC for peritoneal disease
Gynaecological
- Recurrent GI and gynaecological malignancy
Gastrointestinal
- Laparoscopic and robotic abdominal and thoracic surgery
- Image-guided liver and hepatopancreatobiliary surgery
- Retroperitoneal tumours
Career
- Specialty Surgical Oncology Hospital and Research Centre, Ghatkopar, MumbaiDirector · 2019–Present
- Sir H N Reliance Foundation Hospital, MumbaiConsultant, GI & Gynaec Oncosurgeon · 2015–Present
- Saifee Hospital, MumbaiChief, Division of Peritoneal Surface Oncology · 2011–Present
Education & Training
- Surgical OncologyTata Memorial Hospital, Mumbai · 2005–2009
- Fellowship, Laparoscopic & Robotic Colorectal SurgerySouth Korea
- Fellowship, GI Oncology & CRS/HIPECMontpellier, France
- Fellowship, CRS & HIPECMedStar Washington Hospital Center (Dr. Paul Sugarbaker)
- Clinical Fellow, Digestive and Minimally Invasive SurgeryL'Hôpital Saint-Eloi, CHU Montpellier, France
- Hepatobiliary SurgeryHumanitas University
Research & Publications
See publications on PubMed (opens in a new tab)
Reviews & guidelines
- 2025The INDEPSO-ISPSM Consensus on Peritoneal Malignancies-Diagnosis and Management of Peritoneal Mesothelioma (opens in a new tab)Indian J Surg Oncol
- 2025The INDEPSO-ISPSM Consensus on Peritoneal Malignancies-Methodology (opens in a new tab)Indian J Surg Oncol
- 2024Do all patients that undergo a 'complete' secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? (opens in a new tab)Pleura Peritoneum
- 2024Two-stage cytoreductive surgery for 'extensive' pseudomyxoma peritonei: A legitimate alternative or salvage strategy? (opens in a new tab)Eur J Surg Oncol
- 2019Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) (opens in a new tab)Indian J Anaesth
- 2018Epidural Hematoma: Vigilance beyond Guidelines (opens in a new tab)Indian J Crit Care Med
- 2016Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases (opens in a new tab)Indian J Surg Oncol
- 2016Cytoreductive Surgery and Peritonectomy Procedures (opens in a new tab)Indian J Surg Oncol
Led by Dr. Mehta
- 2026Laparoscopic Posterior Sectionectomy Extended to the Right Hepatic Vein: A Low-Cost, Resource-Efficient Approach (opens in a new tab)Ann Surg Oncol
- 2023High-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role? (opens in a new tab)Indian J Surg Oncol
- 2023Bilateral Thoracic Cytoreductive Surgery for Pseudomyxoma Peritonei of Appendiceal Origin (opens in a new tab)Indian J Surg Oncol
- 2022Feasibility and Safety of Taxane-PIPAC in Patients with Peritoneal Malignancies-a Retrospective Bi-institutional Study (opens in a new tab)Indian J Surg Oncol
- 2021Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study (opens in a new tab)Ann Surg Oncol
- 2021Primary Squamous Cell Carcinoma of the Sternum (opens in a new tab)Ann Thorac Surg
- 2020Concomitant aortocaval resection for germ cell tumour (opens in a new tab)Indian J Med Res
- 2020Delayed Management of Chemoport Complication (opens in a new tab)Indian J Surg Oncol
- 2020Aortic Resection with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Case Report (opens in a new tab)Indian J Surg Oncol
- 2019Correlation Between Pelvic Peritoneal Disease and Nodal Metastasis in Advanced Ovarian Cancer: Can Intraoperative Findings Define the Need for Systematic Nodal Dissection? (opens in a new tab)Indian J Surg Oncol
- 2019Impact of Radicality Versus Timing of Surgery in Patients with Advanced Ovarian Cancer (Stage III C) Undergoing CRS and HIPEC-a Retrospective Study by INDEPSO (opens in a new tab)Indian J Surg Oncol
- 2018Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study (opens in a new tab)Eur J Surg Oncol
- 2018Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification (opens in a new tab)Eur J Surg Oncol
- 2017CRS and HIPEC for PMP-Use of the LC-CUSUM to Determine the Number of Procedures Required to Attain a Minimal Level of Proficiency in Delivering the Combined Modality Treatment (opens in a new tab)Indian J Surg Oncol
- 2012Laparoscopic versus open distal pancreatectomy: a single-institution case-control study (opens in a new tab)Surg Endosc
Co-authored
- 2026Systematic total parietal peritonectomy for peritoneal mesothelioma-perioperative and oncological outcomes in an Indian cohort of 100 patients (opens in a new tab)Eur J Surg Oncol
- 2026Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer (opens in a new tab)Front Immunol
- 2026MORPHology and Inter-observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS: The MORPHEUS study (opens in a new tab)Ann Surg Oncol
- 2025Role of EpCAM-Positive Exosomes in Ovarian Cancer: MiRNA Signatures of Chemoresistance and Disease Progression (opens in a new tab)Asia Pac J Clin Oncol
- 2025Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer (opens in a new tab)Front Oncol
- 2024Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study (opens in a new tab)J Gynecol Oncol
- 2023Paul Sugarbaker and Peritoneal Surface Oncology in India (opens in a new tab)Indian J Surg Oncol
- 2023Long-Term Survival in Patients Treated by Cytoreductive Surgery with or Without HIPEC for Peritoneal Surface Malignancies-A report from the Indian HIPEC Registry (opens in a new tab)Indian J Surg Oncol
- 2023Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer (opens in a new tab)J Ovarian Res
- 2022Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer (opens in a new tab)Front Oncol
- 2022Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups (opens in a new tab)BMC Surg
- 2021Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study (opens in a new tab)BMJ Open
- 2021Greater-omentum lesion-score (GOLS) as a predictor of residual disease in different regions of the peritoneal cavity in patients undergoing interval cytoreductive surgery for advanced ovarian cancer and its potential clinical utility (opens in a new tab)Eur J Surg Oncol
- 2021Human papillomavirus infection: Is it associated with epithelial ovarian cancer? (opens in a new tab)Indian J Med Microbiol
- 2021Limitations of the PRODIGE 7 trial (opens in a new tab)Lancet Oncol
- 2021Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence- results of a prospective multi-centre study (opens in a new tab)Eur J Surg Oncol
- 2021Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer (opens in a new tab)Eur J Surg Oncol
- 2021Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study (opens in a new tab)Ann Surg Oncol
- 2021Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications (opens in a new tab)Eur J Surg Oncol
- 2021A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO (opens in a new tab)Eur J Surg Oncol
- 2020Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index (opens in a new tab)Colorectal Dis
- 2020The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising From Various Primary Tumors (opens in a new tab)Ann Surg Oncol
- 2020Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease? (opens in a new tab)Eur J Surg Oncol
- 2019Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study (opens in a new tab)Eur J Surg Oncol
- 2019Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Initial Experience from Indian Centers and a Review of Literature (opens in a new tab)Indian J Surg Oncol
- 2019Failure-to-Rescue Following Cytoreductive Surgery with or Without HIPEC is Determined by the Type of Complication-a Retrospective Study by INDEPSO (opens in a new tab)Indian J Surg Oncol
- 2019Analysis of Clinical Outcomes of Pseudomyxoma Peritonei from Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Retrospective Study from INDEPSO (opens in a new tab)Indian J Surg Oncol
- 2019Chasing Rainbows? the Possibility of "Cure" in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC-a Retrospective Study by INDEPSO (opens in a new tab)Indian J Surg Oncol
- 2019The Current Status of Peritoneal Surface Oncology in India (opens in a new tab)Indian J Surg Oncol
- 2019Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO) (opens in a new tab)Eur J Surg Oncol
- 2018Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry (opens in a new tab)Int J Hyperthermia
- 2017Setting up of the Indian HIPEC Registry: A Registry for Indian Patients with Peritoneal Surface Malignancies (opens in a new tab)Indian J Surg Oncol
- 2016Oncovascular compartmental resection for retroperitoneal soft tissue sarcoma with vascular involvement (opens in a new tab)J Vasc Surg
- 2016The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases (opens in a new tab)Indian J Surg Oncol
Awards & Leadership
- Society of Peritoneal Surface Oncology of IndiaCo-founder · 2017
- Indian HIPEC RegistryCo-founder · 2017
- Rotary International Ambassadorial Scholarship2009–2010
- Asian Peritoneal Surface Malignancy Group (APSMG)Executive Committee member
- Young Achievers AwardJCI
- Cancer Charity TrustFounder Member and Trustee
- Asha FoundationFounder Member
- Reevive crowdfunding platform for cancer patientsCo-founder (with Tata Memorial Hospital)